Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Chiesi gets ex-US rights to Protalix's Phase III Fabry candidate; deal expanded to include US rights

Executive Summary

Protalix BioTherapeutics Inc. licensed Chiesi Farmaceutici SPA exclusive rights to develop and commercialize its Phase III PRX102 (pegunigalsidase alfa) for Fabry disease in all territories except the US where Protalix retains rights.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register